CD70 and renal cell carcinoma: The therapeutic landscape for CD70-targeted therapies in RCC is rapidly evolving with multiple strategies under investigation such as monoclonal antibodies, antibody-drug conjugates, CAR-T cells, and CAR-NK cells.